• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
ZHU Jie, ZHANG Chen, WU Jianbing, ZHANG Yihua, HUANG Zhangjian. Status and progress of tetravalent platinum prodrugs[J]. Journal of China Pharmaceutical University, 2022, 53(5): 613-622. DOI: 10.11665/j.issn.1000-5048.20220512
Citation: ZHU Jie, ZHANG Chen, WU Jianbing, ZHANG Yihua, HUANG Zhangjian. Status and progress of tetravalent platinum prodrugs[J]. Journal of China Pharmaceutical University, 2022, 53(5): 613-622. DOI: 10.11665/j.issn.1000-5048.20220512
shu

Status and progress of tetravalent platinum prodrugs

  • Center of Drug Discovery, China Pharmaceutical University, Nanjing 210009, China

Funds: This study was supported by the National Natural Science Foundation of China (No.81822041, No.21977116, No.82173681)
More Information
  • Received Date: February 11, 2022
  • Revised Date: April 30, 2022
    Graphical Abstract
    • Abstract
  • Bivalent platinum drugs [Pt(II)] represented by cisplatin are the first-line drugs in clinical application, but they have defects such as severe side-effects, poor bioavailability and drug resistance.Tetravalent platinum [Pt(IV)] complexes, derivatives of Pt(II) with different substitutions in axial positions, can be reduced to Pt(II) under the action of reductants in tumor, and can therefore act as a prodrug of Pt(II).Axial substituents can improve platinum drugs'' pharmacokinetics, selectivity and bioactivity, as well as achieve anti-tumor effect by additional cytotoxic mechanisms other than DNA damage, which can overcome the drug resistance to Pt(II).This review outlines the resistance mechanisms of platinum drugs, including platinum transport, detoxification, autophagy, and DNA repair, etc.It also summarizes the structure-activity relationship, main types and advances of tetravalent platinum prodrugs, as well as possible approach to solve platinum drug resistance.
    • FullText(HTML)
    • References (52)
  • [1]
    . Nature，1969，222（5191）：385-386.
    [2]
    Wheate NJ，Walker S，Craig GE，et al. The status of platinum anticancer drugs in the clinic and in clinical trials［J］. Dalton Trans，2010，39（35）：8113-8127.
    [3]
    Cleare MJ，Hoeschele JD. Studies on the antitumor activity of group VIII transition metal complexes. Part I. Platinum （II） complexes［J］. Bioinorg Chem，1973，2（3）：187-210.
    [4]
    Shimada M，Itamochi H，Kigawa J. Nedaplatin：a cisplatin derivative in cancer chemotherapy［J］. Cancer Manag Res，2013，5：67-76.
    [5]
    McKeage MJ. Lobaplatin：a new antitumour platinum drug［J］. Expert Opin Investig Drugs，2001，10（1）：119-128.
    [6]
    Gately D，Howell S. Cellular accumulation of the anticancer agent cisplatin：a review［J］. Br J Cancer，1993，67（6）：1171-1176.
    [7]
    Safaei R，Katano K，Samimi G，et al. Cross-resistance to cisplatin in cells with acquired resistance to copper［J］. Cancer Chemother Pharmacol，2004，53（3）：239-246.
    [8]
    Todd RC，Lippard SJ. Inhibition of transcription by platinum antitumor compounds［J］. Metallomics，2009，1（4）：280-291.
    [9]
    Zimmermann T，Zeizinger M，Burda JV. Cisplatin interaction with cysteine and methionine，a theoretical DFT study［J］. J Inorg Biochem，2005，99（11）：2184-2196.
    [10]
    Fuertes MA，Alonso C，Pérez JM. Biochemical modulation of cisplatin mechanisms of action：enhancement of antitumor activity and circumvention of drug resistance［J］. Chem Rev，2003，103（3）：645-662.
    [11]
    Ginson D. Platinum（iv） anticancer prodrugs：hypotheses and facts［J］. Dalton Trans，2016，45（33）：12983-12991.
    [12]
    Pendyala L，Krishnan BS，Walsh JR，et al. Studies on the human metabolism of iproplatin［J］. Cancer Chemother Pharmacol，1989，25（1）：10-14.
    [13]
    Awuah SG，Zheng YR，Bruno PM，et al. A Pt（IV） pro-drug preferentially targets indoleamine-2，3-dioxygenase，providing enhanced ovarian cancer immuno-chemotherapy［J］. J Am Chem Soc，2015，137（47）：14854-14857.
    [14]
    Gandioso A，Shaili E，Massaguer A，et al. An integrin-targeted photoactivatable Pt（IV） complex as a selective anticancer pro-drug：synthesis and photoactivation studies［J］. Chem Commun （Camb），2015，51（44）：9169-9172.
    [15]
    Perland E，Fredriksson R. Classification systems of secondary active transporters［J］. Trends Pharmacol Sci，2017，38（3）：305-315.
    [16]
    Yonezawa A，Masuda S，Yokoo S，et al. Cisplatin and oxaliplatin，but not carboplatin and nedaplatin，are substrates for human organic cation transporters （SLC22A1-3 and multidrug and toxin extrusion family）［J］. J Pharmacol Exp Ther，2006，319（2）：879-886.
    [17]
    Gao J，Wang WY. Knockdown of galectin-1 facilitated cisplatin sensitivity by inhibiting autophagy in neuroblastoma cells［J］. Chem Biol Interact，2019，297：50-56.
    [18]
    Aguilar A. Kidney cancer：OCT2 demethylation cracks open oxaliplatin resistance［J］. Nat Rev Nephrol，2016，12（10）：581.
    [19]
    Lasorsa A，Nardella MI，Rosato A，et al. Mechanistic and structural basis for inhibition of copper trafficking by platinum anticancer drugs［J］. J Am Chem Soc，2019，141（30）：12109-12120.
    [20]
    Zimmermann T，Burda JV. Cisplatin interaction with amino acids cysteine and methionine from gas phase to solutions with constant pH［J］. Interdiscip Sci Comput Life Sci，2010，2（1）：98-114.
    [21]
    Liang S，Han LQ，Mu WW，et al. Carboplatin-loaded SMNDs to reduce GSH-mediated platinum resistance for prostate cancer therapy［J］. J Mater Chem B，2018，6（43）：7004-7014.
    [22]
    Kimura T，Kambe T. The functions of metallothionein and ZIP and ZnT transporters：an overview and perspective［J］. Int J Mol Sci，2016，17（3）：336.
    [23]
    Kawahara B，Ramadoss S，Chaudhuri G，et al. Carbon monoxide sensitizes cisplatin-resistant ovarian cancer cell lines toward cisplatin via attenuation of levels of glutathione and nuclear metallothionein［J］. J Inorg Biochem，2019，191：29-39.
    [24]
    Fukuda T，Oda K，Wada-Hiraike O，et al. The anti-malarial chloroquine suppresses proliferation and overcomes cisplatin resistance of endometrial cancer cells via autophagy inhibition［J］. Gynecol Oncol，2015，137（3）：538-545.
    [25]
    Zhao L，Li W，Zhou YX，et al. The overexpression and nuclear translocation of Trx-1 during hypoxia confers on HepG2 cells resistance to DDP，and GL-V9 reverses the resistance by suppressing the Trx-1/Ref-1 axis［J］. Free Radic Biol Med，2015，82：29-41.
    [26]
    Ayers PW，Parr RG，Pearson RG. Elucidating the hard/soft acid/base principle：a perspective based on half-reactions［J］. J Chem Phys，2006，124（19）：194107.
    [27]
    Chen J，Gao CZ，Zhang Y，et al. Inorganic nano-targeted drugs delivery system and its application of platinum-based anticancer drugs［J］. J Nanosci Nanotechnol，2017，17（1）：1-17.
    [28]
    Browning RJ，Reardon PJT，Parhizkar M，et al. Drug delivery strategies for platinum-based chemotherapy［J］. ACS Nano，2017，11（9）：8560-8578.
    [29]
    Du J，Cullen JJ，Buettner GR. Ascorbic acid：chemistry，biology and the treatment of cancer［J］. Biochim Biophys Acta，2012，1826（2）：443-457.
    [30]
    Michelet F，Gueguen R，Leroy P，et al. Blood and plasma glutathione measured in healthy subjects by HPLC：relation to sex，aging，biological variables，and life habits［J］. Clin Chem，1995，41（10）：1509-1517.
    [31]
    Gamcsik MP，Kasibhatla MS，Teeter SD，et al. Glutathione levels in human tumors［J］. Biomarkers，2012，17（8）：671-691.
    [32]
    Kennedy L，Sandhu JK，Harper ME，et al. Role of glutathione in cancer：from mechanisms to therapies［J］. Biomolecules，2020，10（10）：E1429.
    [33]
    Choi S，Filotto C，Bisanzo M，et al. Reduction and anticancer activity of platinum（IV） complexes［J］. Inorg Chem，1998，37（10）：2500-2504.
    [34]
    Gibbons GR，Wyrick S，Chaney SG. Rapid reduction of tetrachloro（D，L-trans）1，2-diaminocyclohexaneplatinum（IV） （tetraplatin） in R/MINI 1640 tissue culture medium［J］. Cancer Res，1989，49（6）：1402-1407.
    [35]
    Perez RP，O''Dwyer PJ，Handel LM，et al. Comparative cytotoxicity of CI-973，cisplatin，carboplatin and tetraplatin in human ovarian carcinoma cell lines［J］. Int J Cancer，1991，48（2）：265-269.
    [36]
    Schilder RJ，LaCreta FP，Perez RP，et al. Phase I and pharmacokinetic study of ormaplatin （tetraplatin，NSC 363812） administered on a day 1 and day 8 schedule［J］. Cancer Res，1994，54（3）：709-717.
    [37]
    Bramwell VH，Crowther D，O''Malley S，et al. Activity of JM9 in advanced ovarian cancer：a phase I-II trial［J］. Cancer Treat Rep，1985，69（4）：409-416.
    [38]
    Clavel M，Monfardini S，Gundersen S，et al. Phase II study of iproplatin （CHIP，JM-9） in advanced testicular cancers progressing after prior chemotherapy［J］. Eur J Cancer Clin Oncol，1988，24（8）：1345-1348.
    [39]
    Petrelli NJ，Creaven PJ，Herrera L，et al. Phase II trial of continuous-infusion iproplatin （CHIP） and 5-fluorouracil （5-FU） in advanced colorectal carcinoma［J］. Cancer Chemother Pharmacol，1989，23（1）：61-62.
    [40]
    Anderson H，Wagstaff J，Crowther D，et al. Comparative toxicity of cisplatin，carboplatin （CBDCA） and iproplatin （CHIP） in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer［J］. Eur J Cancer Clin Oncol，1988，24（9）：1471-1479.
    [41]
    Bouchal P，Jarkovsky J，Hrazdilova K，et al. The new platinum-based anticancer agent LA-12 induces retinol binding protein 4 in vivo［J］. Proteome Sci，2011，9（1）：68.
    [42]
    Zheng YR，Suntharalingam K，Johnstone TC，et al. Pt（IV） prodrugs designed to bind non-covalently to human serum albumin for drug delivery［J］. J Am Chem Soc，2014，136（24）：8790-8798.
    [43]
    Zanellato I，Bonarrigo I，Sardi M，et al. Evaluation of platinum-ethacrynic acid conjugates in the treatment of mesothelioma［J］. ChemMedChem，2011，6（12）：2287-2293.
    [44]
    Kasparkova J，Kostrhunova H，Novakova O，et al. A photoactivatable platinum（IV） complex targeting genomic DNA and histone deacetylases［J］. Angew Chem Int Ed Engl，2015，54（48）：14478-14482.
    [45]
    Johnson SW，Swiggard PA，Handel LM，et al. Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and-resistant human ovarian cancer cells［J］. Cancer Res，1994，54（22）：5911-5916.
    [46]
    Wang ZG，Xu ZF，Zhu GY. A platinum（IV） anticancer prodrug targeting nucleotide excision repair to overcome cisplatin resistance［J］. Angew Chem Int Ed Engl，2016，55（50）：15564-15568.
    [47]
    Becherel OJ，Jakob B，Cherry AL，et al. CK2 phosphorylation-dependent interaction between aprataxin and MDC1 in the DNA damage response［J］. Nucleic Acids Res，2010，38（5）：1489-1503.
    [48]
    Chen FH，Pei SN，Wang X，et al. Emerging JWA-targeted Pt（IV） prodrugs conjugated with CX-4945 to overcome chemo-immune-resistance［J］. Biochem Biophys Res Commun，2020，521（3）：753-761.
    [49]
    Xue X，You S，Zhang Q，et al. Mitaplatin increases sensitivity of tumor cells to cisplatin by inducing mitochondrial dysfunction［J］. Mol Pharm，2012，9（3）：634-644.
    [50]
    Neumann W，Crews BC，Sárosi MB，et al. Conjugation of cisplatin analogues and cyclooxygenase inhibitors to overcome cisplatin resistance［J］. ChemMedChem，2015，10（1）：183-192.
    [51]
    Oliveira BL，Stenton BJ，Unnikrishnan VB，et al. Platinum-triggered bond-cleavage of pentynoyl amide and N-propargyl handles for drug-activation［J］. J Am Chem Soc，2020，142（24）：10869-10880.
    [52]
    Sun T，Lv T，Wu JB，et al. General strategy for integrated bioorthogonal prodrugs：Pt（II）-triggered depropargylation enables controllable drug activation in vivo［J］. J Med Chem，2020，63（22）：13899-13912.
    • Related Articles

  • Related Articles

    [1]SHANG Feiyang, LIU Chengbo, TAN Hongzhou, HE Bing, HE Liqin. Design, synthesis and antiplatelet aggregation activity of 3-acetyl-7-hydroxycoumarin derivatives[J]. Journal of China Pharmaceutical University, 2024, 55(3): 367-374. DOI: 10.11665/j.issn.1000-5048.2023072901
    [2]DAI Weiguo, TAN Hongzhou, GU Hongxia, HE Bing, HE Liqin, HUANG Peng. Design, synthesis and anti-platelet aggregation activity of paeonol oxime derivatives[J]. Journal of China Pharmaceutical University, 2022, 53(5): 535-541. DOI: 10.11665/j.issn.1000-5048.20220504
    [3]WANG Xiaoli, WANG Zhaoya, WANG Linna, JI Hui, ZHANG Yihua, YIN Jian. Design, synthesis and evaluation of hydrogen sulfide-releasing derivatives of ring opening 3-n-butylphthalide as novel platelet aggregation inhibitors[J]. Journal of China Pharmaceutical University, 2016, 47(2): 158-162. DOI: 10.11665/j.issn.1000-5048.20160205
    [4]FANG Jiangen, WANG Xuliang, LING Jingjing, YIN Wei, XU Jinyi, JI Hui, ZHANG Yihua. Synthesis and antiplatelet aggregation/antioxidant activity of 3-alkyl-benzo［c］ selenophen-1(3H)-ones[J]. Journal of China Pharmaceutical University, 2015, 46(5): 552-555. DOI: 10.11665/j.issn.1000-5048.20150506
    [5]WU Mingming, FANG Lei, GOU Shaohua, CHEN Li. 以2-甲基-2-取代苯氧基丙酸为离去基团的铂(Ⅱ)配合物的合成、表征及细胞毒活性[J]. Journal of China Pharmaceutical University, 2013, 44(4): 303-306. DOI: 10.11665/j.issn.1000-5048.20130403
    [6]YANG Chunyu, HUANG Zhangjian, LING Jingjing, JI Hui, LAI Yisheng, XU Jinyi, PENG Sixun, ZHANG Yihua. Synthesis and evaluation of carbamate-isosorbide-3-n-butylphthalide ring opening derivative trihybrids as novel platelet aggregation inhibitors[J]. Journal of China Pharmaceutical University, 2013, 44(3): 202-206. DOI: 10.11665/j.issn.1000-5048.20130302
    [7]ZHANG Bo-yu, SHAN Jia-qi, LIU Lin, JIAO Bo, SUN Hong-bin. Synthesis and antiplatelet aggregation activities of prasugrel derivatives[J]. Journal of China Pharmaceutical University, 2011, 42(4): 305-309.
    [8]Synthesis and anti-platelet aggregation activity of substituted (E)-1，2-diarylethene compounds[J]. Journal of China Pharmaceutical University, 2010, 41(5): 419-423.
    [9]LI Bao-quan, LI Nian-guang, FENG Feng, TANG Yu-ping, DUAN Jin-ao. Synthesis and anti-platelet aggregation activities of ferulic acid esters[J]. Journal of China Pharmaceutical University, 2009, 40(6): 486-490.
    [10]Synthesis and Antiplatelet Aggregation of N Acylated Tetrahydrobenzylisoquinoline[J]. Journal of China Pharmaceutical University, 1997, (5): 3+6-7.

Catalog

    Get Citation
    PDF
    XML
    Article views (1046) PDF downloads (1215) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：308650

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return